Trial Profile

A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain Amyloidosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linvoseltamab (Primary) ; Sarilumab (Primary) ; Dexamethasone; Dexamethasone; Diphenhydramine; Paracetamol; Tocilizumab
Indications Amyloid light-chain amyloidosis
Focus Adverse reactions; Therapeutic Use
Acronyms LINKER-AL2
Sponsors Regeneron Pharmaceuticals

Most Recent Events

02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
22 May 2026 According to Regeneron Pharmaceuticals media release, the data from the trial will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.
22 May 2026 Results presented in the Regeneron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com